17:43:26 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
ArcticZymes Technologies är verksamma inom bioteknik. Bolaget specialiserar sig inom forskning och utveckling av läkemedel för behandling av sjukdomar som belastar immunsystemet. Störst inriktning återfinns inom utveckling av glukaner, framtagande av immunstimulerande medel, samt analys av enzymer. Visionen är att testa och utveckla medicinen för att sedan föra vidare dessa i användning för olika RNA och DNA processer. Bolaget gick tidigare under namnet Biotec Pharmacon och har sitt huvudkontor i Tromsö.

Kalender

2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-20 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning AZT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2020-01-06 Extra Bolagsstämma 2020
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning AZT 0.00 NOK
2019-05-15 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-10-18 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning AZT 0.00 NOK
2018-05-07 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-01 Bokslutskommuniké 2017
2017-10-19 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning AZT 0.00 NOK
2017-05-11 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-02 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning AZT 0.00 NOK
2016-05-11 Årsstämma 2016
2016-04-19 Kvartalsrapport 2016-Q1
2016-02-11 Bokslutskommuniké 2015
2016-02-11 Kapitalmarknadsdag 2016
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning AZT 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-05 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-15 Ordinarie utdelning AZT 0.00 NOK
2014-05-14 Årsstämma 2014
2014-04-30 Kvartalsrapport 2014-Q1
2014-02-14 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-28 Ordinarie utdelning
2013-05-27 Årsstämma 2013
2013-05-07 Kvartalsrapport 2013-Q1
2013-02-01 Extra Bolagsstämma 2013
2013-01-07 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-10 Kvartalsrapport 2012-Q2
2012-05-07 Kvartalsrapport 2012-Q1
2012-05-07 Årsstämma 2012
2012-05-07 Ordinarie utdelning AZT 0.00 NOK
2012-02-21 Bokslutskommuniké 2011
2011-11-08 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-13 Kvartalsrapport 2011-Q1
2011-05-13 Årsstämma 2011
2011-05-12 Ordinarie utdelning
2011-02-17 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-05-11 Kvartalsrapport 2010-Q1
2010-05-04 Årsstämma 2010
2010-03-03 Bokslutskommuniké 2009
2020-10-08 17:05:00

Tromsø, 08 October, 2020:  ArcticZymes AS, a subsidiary of ArcticZymes Technologies ASA (OSE:AZT), announces that it has entered into a supply and distribution agreement with precision medicine company Jiangsu Simcere Diagnostics, Nanjing, China for the supply of Heat-Labile Salt Active Nuclease (HL-SAN) to be used in the development and manufacturing of Simcere's sequencing assays.

HL-SAN is a critical component of Simcere Diagnostics' infectious disease metagenomic assays.  In particular, the nuclease supplied by ArcticZymes plays a key role in the removal of host DNA from the sample.  This results in a streamlined and efficient sample preparation process that reduces background noise from the assay.  Metagenomic assays are extremely sensitive to competing background noise.  Fortunately, HL-SAN's unique capability to interact with salt provides Simcere the best host DNA removal solution available on the market.

Simcere Pharmaceutical Group, the parent of Simcere Diagnostics, is recognized as one of the "Top 10 Innovative Pharmaceutical Enterprises in China" and "Top 100 Pharmaceutical Manufacturing Enterprises in China".  Simcere has three R&D centers including Boston in the United States and focuses on oncology, central nervous system disease, and autoimmune disease therapeutic and diagnostic areas with a diverse portfolio of products.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"We look forward to supporting Simcere Diagnostics in the development and future commercialization of their innovative sequencing assays as well as other future technologies. This is just the beginning of a long-term relationship together where ArcticZymes' novel enzyme technologies and scientific competence will aid Simcere Diagnostics in marketing best in class sequencing technologies. The agreement marks the first step for ArcticZymes in becoming a long-term supplier of its enzymes to commercial partners in China."

Simcere Diagnostics CEO, Yong Ren said:

"Simcere Diagnostics is excited to collaborate with ArcticZymes AS.  This global collaboration not only helps Simcere in the development and commercialization of its metagenomic products, it also provides our friend ArcticZymes with a market penetration opportunity to the Chinese market.  We plan to work closely in the future to explore additional means to strengthen our partnership and achieve additional penetration in China."

For more information, please contact:

ArcticZymes Technologies    
Jethro Holter, CEO                                                     Tel: +47 46 85 91 46
                                                                                    Email: Jethro.holter@arcticzymes.com

About ArcticZymes AS

ArcticZymes develops, produces and markets novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth markets where rapid technological developments are creating a strong demand for new and improved enzymes. Some of its enzymes' unique features include heat lability and activity in challenging environments as well as customized, engineered novel features which can be integrated to power the technologies of commercial partners.

All ArcticZymes products are ISO13485 certified.

For more information, please visit: www.arcticzymes.com

About Simcere Diagnostics

Founded by Simcere Pharmaceutical Group in 2017, Simcere Diagnostics is a precision medicine company based in China and led by a team of highly experienced professionals in medical genomics and informatics. Utilizing various state-of-the-art technology platforms including Next Generation Sequencing, Nanopore sequencing, MassARRAY® genotyping, digital PCR, as well as advanced bioinformatics, Simcere Diagnostics is committed to fulfilling the unmet medical needs in disease diagnosis, treatment guidance, and progress monitoring via cost-effective and personalized solutions. Simcere Diagnostics is dedicated to developing cutting-edge diagnostic products in the clinical areas of cancer, central nervous system diseases, infectious diseases, pharmacogenomics, and autoimmune disorders.